「ヴィアレブ™」について、米国FDAより進行期パーキンソン病成人患者さんの治療薬として承認を取得

共同通信PRワイヤー / 2024年11月14日 11時0分

2．Aldred, J., et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurol Ther. 2023 Dec;12(6):1937-1958.

3．"Motor fluctuations." Parkinson's Foundation. Available at: https://www.parkinson.org/library/fact-sheets/motor-fluctuations#:~:text=As%20levodopa%20begins%20to%20lose,are%20at%20their%20highest%20point. Accessed October 16, 2024.

4．"Off" Time in Parkinson's Disease." The Michael J. Fox Foundation for Parkinson's Research. Available at: https://www.michaeljfox.org/time-parkinsons-disease. Accessed October 16, 2024.

5．"About Parkinson's: Parkinson's 101." The Michael J. Fox Foundation for Parkinson's　Research. Available at: https://www.michaeljfox.org/understanding-parkinsons/i-have-got-what.php#q2. Accessed October 16, 2024.

6．"Statistics." Parkinson's Foundation. Available at: https://www.parkinson.org/understanding-parkinsons/statistics#:~:text=Nearly%2090%2C000%20people%20in%20the,worldwide%20are%20living%20with%20PD. Accessed October 16, 2024.